The latest update is out from Renerve Limited ( (AU:RNV) ).
ReNerve Limited has announced the issuance of 666,212 fully paid ordinary shares at an issue price of $0.1489 per share, under section 708A(5)(e) of the Corporations Act 2001. This move is part of the company’s strategy to bolster its financial position, enabling further development and commercialization of its innovative nerve repair solutions, potentially enhancing its market position and offering benefits to stakeholders.
More about Renerve Limited
ReNerve Limited (ASX:RNV) is a medical device company specializing in advanced nerve repair and regeneration solutions. The company focuses on commercializing cutting-edge medical devices and tissue-engineering products aimed at addressing significant unmet needs for patients with peripheral nerve damage, thereby improving patient outcomes through scientifically backed products.
YTD Price Performance: -34.29%
Average Trading Volume: 152,586
Find detailed analytics on RNV stock on TipRanks’ Stock Analysis page.